key: cord-0737226-r3m8sbqf authors: Venzon, Mericien; Cadwell, Ken title: COVID-19 and the forgotten organ: prolonged changes to the metabolic output of the gut microbiome date: 2021-11-17 journal: Gastroenterology DOI: 10.1053/j.gastro.2021.11.017 sha: d717a10767d023f50fb098ee935acc8e67b3a1bb doc_id: 737226 cord_uid: r3m8sbqf nan The metabolic byproducts and extraordinary coding potential of the dense microbial community inhabiting the gastrointestinal tract have led investigators to describe the gut microbiota as the "forgotten organ", highlighting the need to consider how its functions are disrupted in disease conditions. Although the ability of intestinal bacteria to competitively exclude enteric pathogens through colonization resistance is now established, numerous studies just in the last decade have uncovered the impact of the gut microbiota on antiviral responses at distal mucosal sites, including the lung. In particular, mouse models demonstrate that efficient activation of both innate and adaptive immune responses during influenza virus infection rely on an intact gut microbiota 1-3 . This long-range protection conferred by the microbiota has been attributed to metabolites secreted by specific bacterial species 4 , raising the possibility that interindividual differences in the microbial community composition influence the severity of viral lung infections. At the dawn of the pandemic it was evident that SARS-CoV-2 caused a devastating respiratory disease in a subset of individuals, with increasing evidence showing that its impacts included significant changes in the gut microbiome composition [5] [6] [7] . COVID-19 associated dysbiosis of the microbiota is characterized by loss of commensal bacterial taxa known to have immunomodulatory activity, such as short-chain fatty acid (SCFA) production. However, it is often difficult to distinguish direct effects of viral infection from the impact of hospitalization and treatment on the microbiome, and the functional significance of these findings required additional investigation. In this issue of Gastroenterology, Zhang and Wan et al. demonstrate the persistence of functional metabolic consequences of dysbiosis associated with severe COVID-19 infection, J o u r n a l P r e -p r o o f thereby solidifying the link between microbiome disruption and disease severity. Their patient cohort included sixty-six hospitalized patients with COVID-19 representing the spectrum of disease severities-mild, moderate, and severe or critical. Importantly, they addressed changes to the gut microbiome that may occur due to hospitalization by including a control cohort of patients hospitalized with community-acquired pneumonia who were negative for COVID-19. Additionally, all patients were antibiotics-naïve at least three-months prior to enrollment, allowing the investigators to decouple the effects of SARS-CoV-2 associated microbial dysbiosis from those precipitated by broad spectrum antibiotics that are frequently administered to individuals hospitalized for COVID-19. Together, these findings reveal a direct link between severity of COVID-19 infection and persistent impairment of the metabolic output from the gut microbiota ( Figure 1 ). An important aspect of this study is that it shows that the previously described reduction in diversity of intestinal bacterial communities in COVID-19 patients leads to consequential changes in the levels of metabolites with known functions in immunity. SCFAs derived from bacteria such as F. prausnitzii, which is a bacterial species reproducibly reduced in patients hospitalized with COVID-19, have received intense scrutiny as mediators of regulatory T cell differentiation and epithelial gene expression 8 . Although less studied in the context of the microbiota-immune axis, numerous effects of L-isoleucine supplementation on immunity have also been documented 9 . Therefore, an important research direction would be to determine whether the gut microbiota dysbiosis observed in severe COVID-19 patients affects the progression and recovery from the disease. It may be particularly worthwhile to examine whether reductions in these metabolites precede certain disease manifestations. Also, it is possible that the prolonged reduction in such microbial metabolites contribute to persistent symptoms such as respiratory, neurological, cardiac, and other problems observed months after the initial infection, a condition broadly referred to as post-acute sequelae of SARS-CoV-2 infection (PASC) or "long COVID" [10] [11] [12] [13] . Long-term evaluation of microbiome dysbiosis may reveal links between specific taxa and symptoms of PASC, information that can be used to identify patients needing more vigilant clinical follow-up. Commensal bacteria calibrate the activation threshold of innate antiviral immunity Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection Microbiota regulates immune defense against respiratory tract influenza A virus infection The microbial metabolite desaminotyrosine protects from influenza through type I interferon Alterations in gut microbiota of patients with COVID-19 during time of hospitalization Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases Isoleucine plays an important role for maintaining immune function Persistent symptoms in patients after acute COVID-19 Follow-up of adults with noncritical COVID-19 two months after symptom onset Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study Immunomodulatory and prophylactic effects of Bifidobacterium bifidum probiotic strain on influenza infection in mice Lactobacillus paracasei feeding improves immune control of influenza infection in mice Probiotics in treatment of viral respiratory infections and neuroinflammatory disorders Gut Dysbiosis during COVID-19 and Potential Effect of